

# Gilead Cell Therapy Grant



The Belgian Hematology Society (BHS), with the support of an unrestricted grant from Gilead Sciences and Kite, a Gilead company, has the pleasure to announce one grant to support research in the field of cellular therapies in hematological disease. Researchers working in hematology are invited to submit their project and apply for the Gilead Cell Therapy Grant.

Terms and conditions to apply are available on the BHS website. The deadline of submission is **Wednesday December** 4<sup>th</sup> 2023 (midnight CET).

The jury will select one winning project based on their innovative character, which will be awarded with 25.000 euro. The award ceremony will take place during the 39<sup>th</sup> BHS General Annual Meeting, February 2-3, 2024.

We are looking forward to receiving outstanding projects that can advance the outcomes of hematological diseases through cellular therapies.

Sincerely, Marc André, President of the BHS







## **Award Criteria**

### Who can apply?

→ Any researcher working on cellular therapies in hematological malignancies can apply.

#### Which projects are eligible?

→ The topic of research is related to translational research within the field of hematology

#### Application requirements?

- → Description of the research project including costs and timeframe (max. 2 pages)
- → Letter of support by a promotor from the department where the research will be performed (max. 1 page)
- → Motivational letter (max. 1 page)
- → List of publications (if applicable)
- → CV

Application forms are available on the BHS website https://bhs.be/practice/gilead-award and must be submitted before December 4<sup>th</sup> 2023.
Only submission through the online form is possible. Submissions sent by e-mail will not be considered.



Contact BHS Secretariat Rue de la loi / Wetstraat 42, 1040 Brussels, Belgium bhs@seauton-international.com www.bhs.be The SAFYHR award has been made possible with grant from Gilead Sciences and Kite, a Gilead company.



